Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision

NCT01188109 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

25

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Pancreatic Neoplasms
Pancreatic Cancer

Interventions

DRUG: Gemcitabine
DRUG: Cisplatin

Sponsor

Emory University